Income Disclosure Scheme immunity and search-material requirements barred further share-transaction additions in unabated assessments under section 15...
Toy balloon tariff classification: functional heading prevails over residual rubber and festive article headings, supporting penalties for deliberate ...
Customs valuation using comparable contemporaneous imports can displace declared value, while missing speaking orders require pursuit before competent...
Foreign customs declarations and importer admissions established undervaluation, supporting sequential value redetermination, differential duty, and m...
Bulk drugs and active pharmaceutical ingredients qualify as "all drugs and medicines" for the specified IGST rate entry because the inclusive statutory definition of "drug" covers substances used as drug components. Their use in manufacture, testing, clinical trials, bioavailability studies or bioequivalence studies does not change their character as drugs. The description-based entry covers APIs even where classified under chemical chapters, and prevails over general chapter-based entries for organic and inorganic chemicals. Imports of bulk drugs or APIs therefore attract IGST at 5% under the relevant rate entry, unless they fall within the separate nil-rated entry.
Bulk drugs and active pharmaceutical ingredients qualify as "all drugs and medicines" for the specified IGST rate entry because the inclusive statutory definition of "drug" covers substances used as drug components. Their use in manufacture, testing, clinical trials, bioavailability studies or bioequivalence studies does not change their character as drugs. The description-based entry covers APIs even where classified under chemical chapters, and prevails over general chapter-based entries for organic and inorganic chemicals. Imports of bulk drugs or APIs therefore attract IGST at 5% under the relevant rate entry, unless they fall within the separate nil-rated entry.
Note: It is a system-generated summary and is for quick reference only.